DURECT Corporation announced that the Board of Directors of DURECT has appointed, effective as of January 4, 2021 Ms. Gail Maderis as a Class I director of DURECT with a term to expire at the 2022 Annual Meeting of Stockholders and Dr. Mohammed Azab as a Class III director of DURECT with a term to expire at the 2021 Annual Meeting of Stockholders. In connection with the appointments, the Board approved an increase in the size of the Board, from eight to ten members, effective as of the Effective Date. Ms. Gail Maderis has served as the President, Chief Executive Officer and a board member of Antiva BioSciences Inc. Prior to that, Ms. Maderis served as the President and Chief Executive Officer of BayBio. Dr. Azab served as President and Chief Medical Officer of Astex Pharmaceuticals Inc. from January 2014 to November 2020, and prior to that, he had served as Astex’s Chief Medical Officer from July 2009 to January 2014.